Conferences
ASCO GU 2024: BCG Shortage: What’s on the Horizon to Replace?
January 26, 2024
ASCO GU 2024: Adverse Effects and Discontinuation of Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer
January 26, 2024
ASCO GU 2024: ABLE-41: Nadofaragene Firadenovec-Vncg Early Use and Outcomes in a Real-World Setting in the United States
January 26, 2024
ASCO GU 2024: Defining Molecular Features Associated with Microsatellite Instability and Response to Immune Checkpoint Blockade in Urothelial Carcinoma
January 26, 2024
ASCO GU 2024: FGFR3 Mutated Urothelial Carcinoma of Bladder or Upper Tract: A Comparative Genomic Landscape Study
January 26, 2024
ASCO GU 2024: Oral APL-1202 in Combination with Tislelizumab as Neoadjuvant Therapy in Patients with MIBC: Interim Analysis of ANTICIPATE Phase II Trial
January 26, 2024
ASCO GU 2024: Urachal and Non-urachal Adenocarcinomas of the Bladder: A Comparative Comprehensive Genomic Profiling Study
January 26, 2024